Tofacitinib for the Treatment of Inflammatory Eye Disease

Who is this study for? Adult patients with uveitis or scleritis
What treatments are being studied? Tofacitinib
Status: Active, not recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2

Non-infectious inflammatory eye disease, such as uveitis and scleritis, is a chronic, auto-immune process that leads to vision loss. While steroids are effective in the short term, the side-effect profile of chronic steroid use necessitates the identification of effective steroid-sparing therapies. Tofacitinib is a small molecule that inhibits the signaling pathways of multiple inflammatory cytokines. The investigators plan to evaluate whether tofacitinib may have efficacy for patients with uveitis and / or scleritis.

Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: No

• diagnosis of uveitis

• a clinical response to steroids

• active disease requiring at least 10mg of prednisone daily (or steroid equivalent)

United States
Washington University in Saint Louis
Saint Louis
Time Frame
Start Date: April 4, 2019
Estimated Completion Date: April 4, 2021
Target number of participants: 5
Experimental: Tofacitinib Treatment
11mg extended-release tofacitinib, once daily, oral
Related Therapeutic Areas
Leads: Washington University School of Medicine

This content was sourced from

Similar Clinical Trials